MXPA02010758A - Matrices de proteina modificada con factor de crecimiento para tejido producido por ingenieria. - Google Patents

Matrices de proteina modificada con factor de crecimiento para tejido producido por ingenieria.

Info

Publication number
MXPA02010758A
MXPA02010758A MXPA02010758A MXPA02010758A MXPA02010758A MX PA02010758 A MXPA02010758 A MX PA02010758A MX PA02010758 A MXPA02010758 A MX PA02010758A MX PA02010758 A MXPA02010758 A MX PA02010758A MX PA02010758 A MXPA02010758 A MX PA02010758A
Authority
MX
Mexico
Prior art keywords
matrix
heparin
drug
protein
regeneration
Prior art date
Application number
MXPA02010758A
Other languages
English (en)
Inventor
Shelly E Sakiyama-Elbert
Original Assignee
Eth Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eth Zuerich filed Critical Eth Zuerich
Publication of MXPA02010758A publication Critical patent/MXPA02010758A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/20—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/23—Carbohydrates
    • A61L2300/236—Glycosaminoglycans, e.g. heparin, hyaluronic acid, chondroitin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602—Type of release, e.g. controlled, sustained, slow
    • A61L2300/604—Biodegradation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Surgery (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Las proteinas se incorporan en el interior de matrices de proteina o de polisacarido para utilizarse en la reparacion, regeneracion y/o remodelacion de tejidos y/o suministro de farmacos. Las proteinas se pueden incorporar de tal forma que se liberen mediante la degradacion de la matriz, mediante la accion y/o difusion enzimatica. Como se demuestra por los ejemplos, un metodo es unir la heparina a la matriz mediante metodos ya sea covalentes o no covalentes, para formar una matriz de heparina. La heparina luego se une de manera no covalente a los factores de crecimiento por union de heparina a la matriz de proteina. Alternativamente, se puede construir una proteina de fusion que contenga una region degradante tal como por ejemplo, un substrato del factor XIIIa y la secuencia de proteina natural. La incorporacion de enlaces degradables entre la matriz y los factores bioactivos puede ser particularmente util cuando se desea un suministro de farmacos a largo plazo, por ejemplo, en el caso de la regeneracion de nervios, en donde se desea variar la velocidad de la liberacion del farmaco espacialmente como una funcion para regeneracion, por ejemplo, rapidamente cerca de la interfaz de tejido viviente y mas lentamente mas lejos en la zona herida. Los beneficios adicionales incluyen la dosis de farmaco total inferior dentro del sistema de suministro, y una regulacion espacial de liberacion que permite que se libere un mayor a porcentaje del farmaco en el momento de la maxima actividad celular.
MXPA02010758A 2000-05-01 2000-05-01 Matrices de proteina modificada con factor de crecimiento para tejido producido por ingenieria. MXPA02010758A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2000/011947 WO2001083522A2 (en) 2000-05-01 2000-05-01 Growth factor modified protein matrices for tissue engineering

Publications (1)

Publication Number Publication Date
MXPA02010758A true MXPA02010758A (es) 2005-05-31

Family

ID=21741346

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02010758A MXPA02010758A (es) 2000-05-01 2000-05-01 Matrices de proteina modificada con factor de crecimiento para tejido producido por ingenieria.

Country Status (9)

Country Link
EP (1) EP1280566B1 (es)
JP (1) JP4608173B2 (es)
AT (1) ATE439876T1 (es)
AU (1) AU2000246922A1 (es)
CA (1) CA2407952C (es)
DE (1) DE60042795D1 (es)
ES (1) ES2330187T3 (es)
MX (1) MXPA02010758A (es)
WO (1) WO2001083522A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7662409B2 (en) 1998-09-25 2010-02-16 Gel-Del Technologies, Inc. Protein matrix materials, devices and methods of making and using thereof
US7247609B2 (en) 2001-12-18 2007-07-24 Universitat Zurich Growth factor modified protein matrices for tissue engineering
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
DE10209822A1 (de) * 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
CA2483778A1 (en) 2002-04-29 2003-11-13 Gel-Del Technologies, Inc. Biomatrix structural containment and fixation systems and methods of use thereof
US8465537B2 (en) 2003-06-17 2013-06-18 Gel-Del Technologies, Inc. Encapsulated or coated stent systems
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
EP1660013A4 (en) 2003-08-26 2011-07-20 Gel Del Technologies Inc BIOMATERIAL AND PROTEIN BIOCOACERVATES, METHODS OF MAKING AND USING THEM
EP1691746B1 (en) 2003-12-08 2015-05-27 Gel-Del Technologies, Inc. Mucoadhesive drug delivery devices and methods of making and using thereof
US7351423B2 (en) 2004-09-01 2008-04-01 Depuy Spine, Inc. Musculo-skeletal implant having a bioactive gradient
EP2237770A4 (en) 2007-12-26 2011-11-09 Gel Del Technologies Inc BIOCOMPATIBLE PROTEIN PARTICLES, PARTICLE DEVICES AND METHODS THEREOF
CA2710798A1 (en) 2007-12-28 2009-07-09 Kuros Biosurgery Ag Pdgf fusion proteins incorporated into fibrin foams
US20110256222A1 (en) 2008-04-10 2011-10-20 Arjo Lysander De Boer Recombinant Protein Enriched in a Heparin Binding Site and/or in a Heparan Sulfate Binding Site
US10016534B2 (en) 2008-11-17 2018-07-10 Gel-Del Technologies, Inc. Protein biomaterial and biocoacervate vessel graft systems and methods of making and using thereof
GB201115910D0 (en) 2011-09-14 2011-10-26 Univ Manchester Peptides

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003525916A (ja) * 1999-04-22 2003-09-02 エイドゲントシッシュ テクニーシェ ホッシュール チューリッヒ モディファイドタンパク質マトリクス
ES2255257T3 (es) * 1999-04-22 2006-06-16 Eidgenossische Technische Hochschule (Eth) Liberacion controlada de factores de crecimiento a partir de matrices que contienen heparina.
DE20010297U1 (de) * 2000-06-08 2000-08-31 ETH Zürich, Zürich Enzymvermittelte Modifizierung von Fibrin zur Gewebemanipulation: Fibrin-Formulierungen mit Peptiden

Also Published As

Publication number Publication date
WO2001083522A2 (en) 2001-11-08
JP2003535055A (ja) 2003-11-25
EP1280566B1 (en) 2009-08-19
CA2407952C (en) 2007-08-07
ATE439876T1 (de) 2009-09-15
CA2407952A1 (en) 2001-11-08
ES2330187T3 (es) 2009-12-07
EP1280566A2 (en) 2003-02-05
DE60042795D1 (de) 2009-10-01
WO2001083522A3 (en) 2002-03-28
AU2000246922A1 (en) 2001-11-12
JP4608173B2 (ja) 2011-01-05

Similar Documents

Publication Publication Date Title
WO2003052091A8 (en) Growth factor modified protein matrices for tissue engineering
MXPA02010758A (es) Matrices de proteina modificada con factor de crecimiento para tejido producido por ingenieria.
Pan et al. Advances in the repair of segmental nerve injuries and trends in reconstruction
JP6144249B2 (ja) ポリペプチド−ポリマー抱合体およびその使用方法
Thomopoulos et al. Enhanced flexor tendon healing through controlled delivery of PDGF‐BB
Nillesen et al. Increased angiogenesis and blood vessel maturation in acellular collagen–heparin scaffolds containing both FGF2 and VEGF
Kearney et al. Macroscale delivery systems for molecular and cellular payloads
Ramburrun et al. A review of bioactive release from nerve conduits as a neurotherapeutic strategy for neuronal growth in peripheral nerve injury
Singh et al. Delivery of VEGF using collagen‐coated polycaprolactone scaffolds stimulates angiogenesis
Madzovska-Malagurski et al. Towards antimicrobial yet bioactive Cu-alginate hydrogels
Hao et al. Collagen/heparin bi‐affinity multilayer modified collagen scaffolds for controlled bFGF release to improve angiogenesis in vivo
ATE392907T1 (de) Bioabsorbierbare kompositmaterialien aus derivatisierter hyaluronsäure
WO2003065881A3 (en) Medical device with coating that promotes endothelial cell adherence and differentiation
WO2007062060A3 (en) Methods and compositions using substance p to promote wound healing
MXPA01010692A (es) Matrices de proteina modificadas para ingenieria de tejidos o liberacion controlada.
WO2005112542A3 (es) Composición para la reparación ósea y cartilaginosa
Doǧan et al. Controlled release of EGF and bFGF from dextran hydrogels in vitro and in vivo
EP2282785B1 (en) Heparin-conjugated fibrin gel and method and kit for preparing the same
Draenert et al. BMP‐2 and bFGF release and in vitro effect on human osteoblasts after adsorption to bone grafts and biomaterials
Hettiaratchi et al. Modulated protein delivery to engineer tissue repair
Mantripragada et al. Injectable chitosan microparticles incorporating bone morphogenetic protein‐7 for bone tissue regeneration
Fang et al. Injectable gel graft for bone defect repair
Haitang et al. Progress in various crosslinking modification for acellular matrix
Park et al. Enhancement of the osteogenic efficacy of osteoblast transplantation by the sustained delivery of basic fibroblast growth factor
Nilasaroya et al. Heparin‐functionalized hydrogels as growth factor‐signaling substrates

Legal Events

Date Code Title Description
FG Grant or registration